Chromocell Therapeutics (CHRO) Competitors $1.34 -0.01 (-0.74%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock CHRO vs. CVKD, KALA, GBIO, EGRX, GDTC, IPA, TPST, TENX, CYCC, and CARAShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Cadrenal Therapeutics (CVKD), KALA BIO (KALA), Generation Bio (GBIO), Eagle Pharmaceuticals (EGRX), CytoMed Therapeutics (GDTC), ImmunoPrecise Antibodies (IPA), Tempest Therapeutics (TPST), Tenax Therapeutics (TENX), Cyclacel Pharmaceuticals (CYCC), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Its Competitors Cadrenal Therapeutics KALA BIO Generation Bio Eagle Pharmaceuticals CytoMed Therapeutics ImmunoPrecise Antibodies Tempest Therapeutics Tenax Therapeutics Cyclacel Pharmaceuticals Cara Therapeutics Chromocell Therapeutics (NYSE:CHRO) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, community ranking, analyst recommendations, earnings and institutional ownership. Do institutionals and insiders hold more shares of CHRO or CVKD? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 48.6% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is CHRO or CVKD more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Cadrenal Therapeutics N/A -142.95%-118.40% Does the MarketBeat Community favor CHRO or CVKD? Cadrenal Therapeutics received 6 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 87.50% of users gave Cadrenal Therapeutics an outperform vote. CompanyUnderperformOutperformChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesCadrenal TherapeuticsOutperform Votes787.50% Underperform Votes112.50% Do analysts rate CHRO or CVKD? Cadrenal Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 113.48%. Given Cadrenal Therapeutics' higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Chromocell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, CHRO or CVKD? Cadrenal Therapeutics is trading at a lower price-to-earnings ratio than Chromocell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38M-$1.24-1.08Cadrenal TherapeuticsN/AN/A-$8.36M-$9.26-1.62 Which has more risk and volatility, CHRO or CVKD? Chromocell Therapeutics has a beta of 3.22, meaning that its share price is 222% more volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 1.1, meaning that its share price is 10% more volatile than the S&P 500. Does the media refer more to CHRO or CVKD? In the previous week, Cadrenal Therapeutics had 2 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 3 mentions for Cadrenal Therapeutics and 1 mentions for Chromocell Therapeutics. Cadrenal Therapeutics' average media sentiment score of 1.43 beat Chromocell Therapeutics' score of 1.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Chromocell Therapeutics Positive Cadrenal Therapeutics Positive SummaryChromocell Therapeutics beats Cadrenal Therapeutics on 7 of the 13 factors compared between the two stocks. Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CHRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$8.84M$3.12B$5.61B$19.87BDividend YieldN/A1.56%5.28%3.83%P/E Ratio-1.0832.9027.1435.60Price / SalesN/A466.20411.8343.81Price / CashN/A168.6838.2517.51Price / Book-0.813.427.064.85Net Income-$7.38M-$72.35M$3.23B$1.02B7 Day Performance24.54%7.27%2.67%1.94%1 Month Performance24.19%17.53%8.82%3.02%1 Year Performance3.88%-17.27%31.44%9.87% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell Therapeutics1.1975 of 5 stars$1.34-0.7%N/A+2.3%$8.84MN/A-1.084Positive NewsShort Interest ↓CVKDCadrenal Therapeutics3.5154 of 5 stars$13.43-0.8%$32.00+138.3%N/A$26.42MN/A-2.014News CoveragePositive NewsShort Interest ↓Gap UpKALAKALA BIO3.7989 of 5 stars$4.09+16.2%$13.50+230.1%-30.7%$26.39M$3.89M-0.3330Positive NewsGap UpGBIOGeneration Bio4.0988 of 5 stars$0.39+0.9%$7.33+1,790.0%-87.5%$26.01M$24.56M-0.18150Positive NewsShort Interest ↓EGRXEagle PharmaceuticalsN/A$1.98-1.3%N/A-37.5%$25.65M$257.55M0.00100Gap DownGDTCCytoMed Therapeutics2.6181 of 5 stars$2.34flat$5.00+113.7%+2.9%$25.60M$69.50K0.00N/APositive NewsGap UpIPAImmunoPrecise Antibodies2.6639 of 5 stars$0.56-2.8%$4.00+620.1%-41.1%$25.42M$24.00M-0.7180News CoverageOptions VolumeTPSTTempest Therapeutics2.5562 of 5 stars$6.86+2.4%$30.00+337.3%-81.5%$25.26MN/A-4.4820News CoverageGap UpTENXTenax Therapeutics1.6714 of 5 stars$6.04-0.7%$17.50+189.7%+68.7%$25.05MN/A-2.449Positive NewsCYCCCyclacel Pharmaceuticals1.1611 of 5 stars$1.62-1.2%N/A-98.9%$24.94M$14K-0.1714CARACara Therapeutics1.4911 of 5 starsN/A$36.00+∞N/A$24.33M$7.14M-0.2580Gap DownHigh Trading Volume Related Companies and Tools Related Companies Cadrenal Therapeutics Competitors KALA BIO Competitors Generation Bio Competitors Eagle Pharmaceuticals Competitors CytoMed Therapeutics Competitors ImmunoPrecise Antibodies Competitors Tempest Therapeutics Competitors Tenax Therapeutics Competitors Cyclacel Pharmaceuticals Competitors Cara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored50-year legend: Here’s exact day stocks will crashGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRO Stock Free CHRO Stock Alerts